公开(公告)号：KR101550873B1

公开(公告)日：2015-09-07

申请号：KR1020140180766

申请日：2014-12-15

Applicant: 이화여자대학교 산학협력단

Inventor： 주웅 ,  박애경 ,  안정혁 ,  성혜윤

IPC: C12Q1/68

Abstract: 본 발명은 ANXA4 (annexin A4) 유전자 프로모터의 CpG 부위의 메틸화 수준을 검출함으로써, 난소암 환자의 항암제 치료 반응성을 예측하기 위한 조성물, 키트 및 방법에 관한 것이다.

Abstract translation: 本发明涉及通过检测膜联蛋白A4（ANXA4）基因启动子的CpG区域的甲基化水平来预测卵巢癌患者中抗癌药物的治疗反应的组合物，试剂盒和方法。

公开(公告)号：KR101539104B1

公开(公告)日：2015-07-23

申请号：KR1020140180772

申请日：2014-12-15

Applicant: 이화여자대학교 산학협력단

Inventor： 주웅 ,  박애경 ,  안정혁 ,  성혜윤

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q1/6844

Abstract: 본발명은 PARP4 (poly (ADP-ribose) polymerase family, member 4) 유전자프로모터의 CpG 부위의메틸화수준을검출함으로써, 난소암환자의항암제치료반응성을예측하기위한조성물, 키트및 방법에관한것이다.

Abstract translation: 本发明涉及通过检测聚（ADP-核糖）聚合酶家族成员4（PARP4）的CpG部分的甲基化状态来预测卵巢癌患者的抗癌药物治疗的反应的组合物，试剂盒和方法 ）基因启动子。

公开(公告)号：KR101539101B1

公开(公告)日：2015-07-23

申请号：KR1020140180769

申请日：2014-12-15

Applicant: 이화여자대학교 산학협력단

Inventor： 주웅 ,  박애경 ,  안정혁 ,  성혜윤

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q1/6844

Abstract: 본발명은 KCNE4 (potassium voltage-gated channel, Isk-related family, member 4) 유전자프로모터의 CpG 부위의메틸화수준을검출함으로써, 난소암환자의항암제치료반응성을예측하기위한조성물, 키트및 방법에관한것이다.

Abstract translation: 本发明涉及通过检测钾电压门控通道的CpG部分的甲基化状态来预测卵巢癌患者的抗癌药物治疗的反应的组合物，试剂盒和方法，Isk相关家族，成员4 （KCNE4）基因启动子。

公开(公告)号：KR101275267B1

公开(公告)日：2013-06-17

申请号：KR1020130022243

申请日：2013-02-28

Applicant: 이화여자대학교 산학협력단

Inventor： 안정혁 ,  성혜윤 ,  주웅

IPC: C12Q1/68 ,  G01N33/574 ,  G01N33/48

CPC classification number: C12Q1/6886 ,  C12Q1/6897 ,  C12Q2600/154 ,  G01N33/48 ,  G01N33/57449

Abstract: PURPOSE: A composition for diagnosing metastatic ovarian cancer using CpG methylation change of a CA9(carbonic anhydrase 9) gene promoter, and a use thereof are provided to measure methylation levels of a certain gene promoter site of genome DNA collected from a patient's sample by MSP(Methylation-Specific PCR), to quickly diagnose the risk of metastasis, and to develop a convenient diagnostic kit. CONSTITUTION: A composition for diagnosing ovarian cancer metastasis or predicting the risk of metastasis contains an agent which measures methylation levels of a CpG site of a CA9 gene promoter. The agent contains: a compound which changes non-methylated cytosine or a methylation-sensitive restriction enzyme; a primer which is specific to a methylated sequence of an AGR2 gene promoter; and a primer which is specific to a non-methylated sequence of the AGR2 gene promoter. A method for providing information for diagnosing ovarian cancer metastasis or predicting the risk of metastasis comprises: a step of measuring the methylation level of the CpG site of the CA9 gene promoter from a patient's sample; and a step of comparing methylation levels with a control group.

Abstract translation: 目的：使用CA9（碳酸酐酶9）基因启动子的CpG甲基化变化诊断转移性卵巢癌的组合物及其用途，用于测定通过MSP从患者样品中收集的基因组DNA的某个基因启动子位点的甲基化水平 （甲基化特异性PCR），以快速诊断转移的风险，并开发便利的诊断试剂盒。 构成：用于诊断卵巢癌转移或预测转移风险的组合物含有测量CA9基因启动子的CpG位点的甲基化水平的试剂。 该试剂含有：改变非甲基化胞嘧啶或甲基化敏感性限制酶的化合物; AGR2基因启动子的甲基化序列特异的引物; 以及对AGR2基因启动子的非甲基化序列特异的引物。 提供用于诊断卵巢癌转移或预测转移风险的信息的方法包括：测量来自患者样品的CA9基因启动子的CpG位点的甲基化水平的步骤; 以及将甲基化水平与对照组进行比较的步骤。